[CNAT] Conatus Pharmaceuticals Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 4.43 Change: 0.66 (17.51%)
Ext. hours: 4.43 Change: 0 (0%)

chart CNAT

Refresh chart

Strongest Trends Summary For CNAT

CNAT is in the long-term down -98% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor for the treatment of acute-on-chronic liver failure; chronic liver failure; post liver transplant clearance of hepatitis C virus infection with sustained viral response; non-alcoholic steatohepatitis; and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-71.33% ROE-82.04% ROI
Current Ratio10.09 Quick Ratio Long Term Debt/Equity0.04 Debt Ratio0.11
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-30 K Cash From Investing Activities4.37 M Cash From Operating Activities-5.95 M Gross Profit
Net Profit-5.98 M Operating Profit-5.96 M Total Assets32.32 M Total Current Assets31.54 M
Total Current Liabilities3.13 M Total Debt1000 K Total Liabilities4.22 M Total Revenue
Technical Data
High 52 week7.5 Low 52 week0.71 Last close0.86 Last change-3.21%
RSI54.13 Average true range0.08 Beta2.1 Volume6.13 M
Simple moving average 20 days0.59% Simple moving average 50 days-35.2% Simple moving average 200 days-73.27%
Performance Data
Performance Week-1.49% Performance Month21.09% Performance Quart-57.84% Performance Half-82.77%
Performance Year-83.24% Performance Year-to-date-78.23% Volatility daily5.84% Volatility weekly13.05%
Volatility monthly26.74% Volatility yearly92.64% Relative Volume56874.5% Average Volume1.08 M
New High New Low


2019-10-11 12:02:04 | Phibro PAHC Suffers Dismal Segmental Sales, Margin Woes

2019-10-11 09:59:01 | Penumbra Enrolls First Patient for Study on Coronary Vessels

2019-09-19 10:29:52 | How Long Will Conatus Pharmaceuticals Inc.'s NASDAQ:CNAT Cash Last?

2019-09-10 09:21:01 | Top Ranked Momentum Stocks to Buy for September 10th

2019-08-19 09:00:01 | Conatus CNAT Upgraded to Strong Buy: Here's What You Should Know

2019-08-07 11:00:03 | Conatus CNAT Beats on Q2 Earnings, Stops Emricasan Studies

2019-08-06 19:25:11 | Conatus Pharmaceuticals CNAT Reports Q2 Loss, Tops Revenue Estimates

2019-08-06 16:05:00 | Conatus Pharmaceuticals Reports Second Quarter 2019 Financial Results and Program Updates

2019-07-31 10:36:02 | Will Conatus Pharmaceuticals CNAT Report Negative Q2 Earnings? What You Should Know

2019-07-25 13:46:33 | Investors Who Bought Conatus Pharmaceuticals NASDAQ:CNAT Shares Five Years Ago Are Now Down 96%

2019-06-26 16:17:31 | Conatus CNAT Stock Price Could Hit Zero

2019-06-26 08:37:12 | Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More

2019-06-26 07:19:56 | The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart

2019-06-26 06:07:10 | Conatus' Emricasan Lags Primary Goal in Liver Function Study

2019-06-25 11:32:45 | NASH Disappointment Forces Conatus To Explore Strategic Alternatives

2019-06-24 17:00:34 | UPDATE 1-Conatus Pharma to explore options as liver disease drug fails trial

2019-06-24 16:19:19 | Conatus Pharma to explore options, liver disease drug fails trial

2019-06-24 16:06:00 | Conatus to Explore Strategic Alternatives and Implement Restructuring Plan

2019-06-24 16:05:00 | Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis

2019-06-12 18:27:10 | CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study

2019-06-01 09:31:01 | Conatus CNAT Down 5.8% Since Last Earnings Report: Can It Rebound?

2019-05-28 11:48:03 | Conatus Down More Than 60% in the Past 90 Days: Here's Why

2019-05-24 09:39:55 | How Many Conatus Pharmaceuticals Inc. NASDAQ:CNAT Shares Do Institutions Own?

2019-05-06 14:53:06 | Conatus' CNAT Earnings, Revenues Miss Estimates in Q1

2019-05-02 19:15:11 | Conatus Pharmaceuticals CNAT Reports Q1 Loss, Lags Revenue Estimates

2019-05-02 18:11:35 | Conatus: 1Q Earnings Snapshot

2019-04-30 07:30:00 | Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis

2019-04-24 10:33:02 | Conatus Pharmaceuticals CNAT May Report Negative Earnings: Know the Trend Ahead of Q1 Release

2019-04-15 07:30:00 | Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

2019-04-07 17:04:02 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

2019-04-07 09:30:01 | Why Is Conatus CNAT Down 37.8% Since Last Earnings Report?

2019-04-02 07:30:00 | Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference

2019-03-27 10:55:02 | Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

2019-03-22 17:43:09 | Conatus CNAT Declines on Failure of NASH Fibrosis Study

2019-03-22 10:49:15 | Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo

2019-03-21 16:05:00 | Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis

2019-03-20 11:10:03 | Conatus CNAT Focuses on Developing NASH Candidate Emricasan

2019-03-13 10:35:02 | Implied Volatility Surging for Conatus CNAT Stock Options

2019-03-13 09:00:00 | Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

2019-03-11 10:57:02 | Conatus' CNAT Q4 Earnings Top Estimates, Emricasan in Focus

2019-03-08 20:24:59 | Edited Transcript of CNAT earnings conference call or presentation 8-Mar-19 9:30pm GMT

2019-03-08 16:05:00 | Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates

2019-03-01 07:30:00 | Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results

2019-02-25 13:20:41 | Is Conatus Pharmaceuticals Inc.’s NASDAQ:CNAT CEO Pay Justified?

2019-02-13 15:36:08 | Conatus CNAT Completes Enrollment in Phase II NASH Study

2019-02-12 07:30:00 | Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis

2019-01-30 08:05:00 | Today's Research Reports on Trending Tickers: Voyager Therapeutics and Conatus Pharmaceuticals

2019-01-29 10:05:03 | Can GW Pharmaceuticals GWPH Deliver a Beat in Q1 Earnings?

2019-01-28 07:30:00 | Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials

2018-12-28 17:40:10 | Conatus CNAT Focuses on Developing NASH Candidate Emricasan